Details of the Drug

General Information of Drug (ID: DM428Y3)

Drug Name

Palomid-529

Synonyms

P-529; Palomid-529; P-529 (inhaled), Paloma; P-529 (ophthalmic), Paloma; P-529 (oral), Paloma; P-529 (topical), Paloma; P-529 drug eluting stent (cardiovascular disease), Paloma; Palomid-529 (inhaled), Paloma; Palomid-529 (ophthalmic), Paloma; Palomid-529 (oral), Paloma; Palomid-529 (topical), Paloma; Palomid-529 drug eluting stent (cardiovascular disease), Paloma; P-529 (intravitreal/subconjunctival), Paloma; Palomid-529 (intravitreal/subconjunctival), Paloma

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 1	[1]
Macular degeneration	9B78.3	Phase 1	[2]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

Cross-matching ID

PubChem CID: 11998575
TTD ID: D06JCO

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Mammalian target of rapamycin complex 1 (mTORC1)	TTX4GLS	MTOR_HUMAN-RPTOR_HUMAN-LST8_HUMAN-AKTS1_HUMAN-DPTOR_HUMAN	Inhibitor	[3]
Target of rapamycin complex 2 MAPKAP1 (MTORC2)	TTWDKCL	SIN1_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (PTEN)	OTOWDUNT	PTEN_HUMAN	Drug Response	[4]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Res. 2008 Nov 15;68(22):9551-7.
2	ClinicalTrials.gov (NCT01033721) Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration (P52901). U.S. National Institutes of Health.
3	Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2. Int J Cancer. 2013 Sep 1;133(5):1222-33.
4	The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells. Endocr Relat Cancer. 2011 Jul 1;18(4):385-400. doi: 10.1530/ERC-11-0045. Print 2011 Aug.